Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients.
暂无分享,去创建一个
Wei Zhang | Wei Zhang | Rong Liu | Weihua Huang | Zhaoqian Liu | Han Yan | Xiaoping Chen | Rong Liu | Hong-Hao Zhou | Xi Li | X. Mao | Honghao Zhou | Xiao-Yuan Mao | Xi Li | Ji-Ye Yin | Zhao-Qian Liu | Xiao-Ping Chen | Zhi-Ying Luo | Han Yan | Wei-Hua Huang | Zhiying Luo | J. Yin
[1] Panos Deloukas,et al. The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.
[2] R. Califf,et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. , 2013, The New England journal of medicine.
[3] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[4] A. Gallus,et al. Standardised initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomised trial, and risk factors for an excessive warfarin response. , 1991, Australian and New Zealand journal of medicine.
[5] A. Israni,et al. Dosing equation for tacrolimus using genetic variants and clinical factors. , 2011, British journal of clinical pharmacology.
[6] F. Kamali,et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. , 2012, Blood.
[7] F. Kamali,et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin , 2004, Clinical pharmacology and therapeutics.
[8] H. Zhou,et al. Development and comparison of a new personalized warfarin stable dose prediction algorithm in Chinese patients undergoing heart valve replacement. , 2012, Die Pharmazie.
[9] Rita Barallon,et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. , 2013, The New England journal of medicine.
[10] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[11] Nicole Soranzo,et al. A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose , 2009, PLoS genetics.
[12] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[13] Jaekyu Shin,et al. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. , 2011, Pharmacogenomics.
[14] J. Hirsh,et al. Interactions of Warfarin with Drugs and Food , 1994, Annals of Internal Medicine.
[15] Christine W. Duarte,et al. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans , 2011, Bioinform..
[16] K E Liu,et al. Improvement of Adequate Use of Warfarin for the Elderly Using Decision Tree-based Approaches , 2013, Methods of Information in Medicine.
[17] B. Horne,et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.
[18] M. Rieder,et al. Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.
[19] D. Tregouet,et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. , 2005, Blood.
[20] Massimo Buscema,et al. Prediction of optimal warfarin maintenance dose using advanced artificial neural networks. , 2014, Pharmacogenomics.
[21] Ling-Zhi Wang,et al. A warfarin‐dosing model in Asians that uses single‐nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9 , 2006, Clinical pharmacology and therapeutics.
[22] S. le Cessie,et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. , 2011, European heart journal.
[23] P. Deloukas,et al. Association of warfarin dose with genes involved in its action and metabolism , 2006, Human Genetics.
[24] D. Wysowski,et al. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. , 2007, Archives of internal medicine.
[25] Wei Zhang,et al. Effect of CYP2C9–VKORC1 interaction on warfarin stable dosage and its predictive algorithm , 2015, Journal of clinical pharmacology.
[26] Eun-Young Kim,et al. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement , 2009, Pharmacogenetics and genomics.
[27] Yusuke Nakamura,et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study , 2013, The Lancet.
[28] N. Eriksson,et al. A randomized trial of genotype-guided dosing of warfarin. , 2013, The New England journal of medicine.